Metformin and myocardial injury in patients With diabetes and ST-segment elevation myocardial infarction: A propensity score matched analysis

Journal of the American Heart Association

Volumn 4, Issue 10, 2015, Pages

  Basnet, Suresh ^a   Kozikowski, Andrzej ^b   Makaryus, Amgad N ^b,c   Pekmezaris, Renee ^b   Zeltser, Roman ^b,c   Akerman, Meredith ^d   Lesser, Martin ^d   Wolf Klein, Gisele ^b  

^a Valley Health   (United States)

^b Northwell Health   (United States)

^c NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Metformin; Myocardial injury; ST segment elevation myocardial infarction

Indexed keywords

CREATINE KINASE MB; METFORMIN; TROPONIN T; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HOSPITAL DISCHARGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; CARDIAC MUSCLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; RISK FACTOR; TIME FACTOR; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CREATINE KINASE, MB FORM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MYOCARDIAL INFARCTION; MYOCARDIUM; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 85006216591     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002314     Document Type: Article

References (33)

1. American Heart Association. Cardiovascular disease and diabetes. Available at: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMat ters/%20Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp. Accessed August 31, 2014.
2. LincoffAM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. J Am Med Assoc. 2007;298:1180-1188.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
4. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-1201.
5. Ghotbi AA, Køber L, Finer N, James WPT, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes a substudy of the SCOUT trial. Diabetes Care. 2013;36:3746-3753.
6. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, MurffHJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601-610.
7. Turner R, Holman R, Stratton I, Cull C, Matthews D, Manley S, Frighi V, Wright D, Neil A, Kohner E. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
8. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57:696-705.
9. Zhao JL, Fan CM, Yang YJ, You SJ, Gao X, Zhou Q, Pei WD. Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction. Cardiovasc Ther. 2013;31:60-64.
10. Lexis CP, Wieringa WG, Hiemstra B, van Deursen VM, Lipsic E, van der Harst P, van Veldhuisen DJ, van der Horst IC. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with STsegment elevation myocardial infarction. Cardiovasc Drugs Ther. 2014;28:163-171.
11. Abualsuod A, Rutland JJ, Watts TE, Pandat S, Delongchamp R, Mehta JL. The effect of metformin use on left ventricular ejection fraction and mortality postmyocardial infarction. Cardiovasc Drugs Ther. 2015;29:265-275.
12. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. J Am Med Assoc. 2014;311: 1526-1535.
13. Mellbin L, Malmberg K, Norhammar AF, Wedel H, Ryden L; Investigators D. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the diabetes mellitus insulin-glucose infusion in acute myocardial infarction (DIGAMI) 2 study. Diabetologia. 2011;54:1308-1317.
14. Paneni F, Costantino S, Cosentino F. Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications. G Ital Cardiol (Rome). 2015;16:225-231.
15. Moussa I, Hermann A, Messenger JC, Dehmer GJ, Weaver WD, Rumsfeld JS, Masoudi FA. The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention. Heart. 2013;99:297-303. doi: 10.1136/heartjnl-2012-303379.
16. National Cardiovascular Data Registry. CathPCI Registry for diagnostic cardiac catheterizations and percutanious coronary interventions. Available at: https://www.ncdr.com/webncdr/cathpci/. Accessed October 3, 2014.
17. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
18. Parsons LS. Performing a 1:N case-control match on propensity score. Proceedings of the 29th Annual SAS Users Group International Conference. May 9-12, 2004. Montréal, Canada.
19. Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17:1218-1225.
20. Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol. 2004;43:2253-2259.
21. Chia S, Senatore F, Raffel OC, Lee H, Frans JT, Jang I-K. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;1:415-423.
22. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244-2248.
23. Selvin E, Bolen S, Yeh H-C, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168:2070-2080.
24. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900-1908.
25. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304-1311.
26. Timmers L, Henriques JP, de Kleijn DP, DeVries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-510.
27. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499.
28. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circulation. 2012;5:288-295.
29. Woo JS, Kim W, Ha SJ, Kim JB, Kim S-J, Kim W-S, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33:2252-2260.
30. Meier J, Gallwitz B, Schmidt W, Mügge A, Nauck M. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart. 2004;90:9-12.
31. Solskov L, Løfgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, Bøtker HE, Schmitz O, Lund S. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 2008;103:82-87.
32. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27:5-16.
33. Paiva MA, Rutter-Locher Z, Gonçalves LM, Providência LA, Davidson SM, Yellon DM, Mocanu MM. Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2011;300:H2123-H2134.